🔗 Share this article WHO Issues Alert Over Acute Shortage of Weight-Loss Injections Less than a tenth of individuals that would benefit from GLP-1 drugs including Wegovy are able to get them, states the World Health Organization as it releases its initial advice on the therapies. With in excess of 1,000,000,000 people worldwide now obese, it is urging more widespread and fairer availability to this class of drugs. Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken. "The latest guidelines affirms that obesity is a lifelong illness that can be addressed with holistic and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and logistical bottlenecks are key hurdles to widespread access to the treatments that can assist patients in reducing considerable body mass, says the body. Weight-Loss Drug Shortage Even in the present most optimistic case, the supply of such drugs would only suffice for about 100 million people – under 10% of the global need, according to the health organization. The guideline calls on countries and companies to expand availability, via strategies including licensing agreements. The intellectual property rights on the active ingredient – the main ingredient of the drug Wegovy – is due to expire in a number of countries in 2026. How Weight-Loss Injections Operate GLP-1 drugs replicate a biological compound to slow digestion, suppress the appetite and enhance satiety so individuals eat less. Patients usually begin shedding pounds after several weeks of beginning the weekly injections. Evidence suggests patients may regain a significant portion within a year of discontinuing the treatment, when their usual hunger come back. To be overweight or obese raises your likelihood for contracting health problems, such as type 2 diabetes, heart disease, stroke, and certain cancers. Obesity affects people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the health agency.
Less than a tenth of individuals that would benefit from GLP-1 drugs including Wegovy are able to get them, states the World Health Organization as it releases its initial advice on the therapies. With in excess of 1,000,000,000 people worldwide now obese, it is urging more widespread and fairer availability to this class of drugs. Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken. "The latest guidelines affirms that obesity is a lifelong illness that can be addressed with holistic and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and logistical bottlenecks are key hurdles to widespread access to the treatments that can assist patients in reducing considerable body mass, says the body. Weight-Loss Drug Shortage Even in the present most optimistic case, the supply of such drugs would only suffice for about 100 million people – under 10% of the global need, according to the health organization. The guideline calls on countries and companies to expand availability, via strategies including licensing agreements. The intellectual property rights on the active ingredient – the main ingredient of the drug Wegovy – is due to expire in a number of countries in 2026. How Weight-Loss Injections Operate GLP-1 drugs replicate a biological compound to slow digestion, suppress the appetite and enhance satiety so individuals eat less. Patients usually begin shedding pounds after several weeks of beginning the weekly injections. Evidence suggests patients may regain a significant portion within a year of discontinuing the treatment, when their usual hunger come back. To be overweight or obese raises your likelihood for contracting health problems, such as type 2 diabetes, heart disease, stroke, and certain cancers. Obesity affects people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the health agency.